OrbiMed et al. back €40m series-B for Enyo Pharma

New backers include OrbiMed, Andera Partners and BPI France, while existing shareholders Sofinnova, Morningside Venture Investments, InnoBio and Inserm Transfert Initiative reinvested in the business.

Iain Dukes, a venture partner at OrbiMed, will take a seat on the board. 

The company intends to use the funds to pursue the phase-II clinical development of its lead product EYP001 during 2018 and 2019.

Previous funding
Sofinnova structured a €1m round of seed capital funding for Enyo in February 2015.

A year later, the GP led a €22m series-A for the business, alongside Morningside Ventures and BPI France. Sofinnova drew equity from its €240m seventh fund at the time. BPI France used its InnoBio fund, a healthcare-focused €173m FCPI fund launched in November 2009.

Company
Founded in 2014, Enyo is a clinical-stage biopharmaceutical company. It develops drug candidates that mimic viruses to modulate host cellular functions. Its lead candidate, EYP001, is currently being evaluated in phase-Ib in patients with chronic hepatitis B.

Based in Lyon, the company also has facilities in Australia.

People
Sofinnova Partners – Rafaèle Tordjman (managing partner).
Enyo Pharma – Jacky Vonderscher (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• Venture